Related Experiment Videos
Molecular surgery for cancer
1Department of Thoracic Surgery, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Abstract:
Advances in the understanding of the process of carcinogenesis may allow prevention, diagnosis, and treatment of cancer to be approached at the molecular level. Studies in our laboratory show that growth factors (transforming growth factor alpha), dominant oncogenes (HER-2/erb B2 and K-ras), and tumor suppressor genes (p53) are functionally important in the maintenance of the malignant phenotype of human non-small-cell lung cancer cells. Application of these findings to clinical problems include the identification of p53 mutations as markers for malignant change in Barrett's epithelium, the use of discordant p53 mutations to diagnose second primary malignant neoplasms in patients with head and neck cancer, and the potential for therapy by the reversal of genetic lesions.
Insights
Understanding molecular targets like growth factors and oncogenes is key for cancer prevention and treatment. Research highlights the role of specific genes (p53) in malignant transformation and potential therapeutic strategies.
Area of Science:
- Molecular oncology
- Cancer biology
- Genetics of carcinogenesis
Background:
- Carcinogenesis research enables molecular-level cancer prevention, diagnosis, and treatment.
- Key molecular players in cancer include growth factors, oncogenes, and tumor suppressor genes.
Purpose of the Study:
- To investigate the functional importance of specific genes in maintaining the malignant phenotype of human non-small-cell lung cancer.
- To explore clinical applications of molecular findings in cancer management.
Main Methods:
- Analysis of growth factors (transforming growth factor alpha).
- Evaluation of dominant oncogenes (HER-2/erb B2, K-ras).
- Assessment of tumor suppressor genes (p53) in non-small-cell lung cancer cells.
Main Results:
- Identified functional importance of transforming growth factor alpha, HER-2/erb B2, K-ras, and p53 in malignant phenotype maintenance.
- Demonstrated p53 mutations as markers for malignant change in Barrett's epithelium.
- Showcased discordant p53 mutations for diagnosing second primary malignant neoplasms in head and neck cancer.
Conclusions:
- Molecular understanding of carcinogenesis facilitates targeted cancer therapies.
- Specific genetic alterations serve as diagnostic markers and therapeutic targets.
- Reversal of genetic lesions holds potential for cancer treatment.